RAPP (STOCKS)
Rapport Therapeutics, Inc. Common Stock
$28.150000
+0.510000 (+1.85%)
Prev close: $27.640000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Abraham N. Ceesay
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,333.08M
- Employees
- 69
- P/E (TTM)
- -10.39
- P/B (TTM)
- 2.57
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
9
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.71 | $-0.79 | +0.0809 | +10.23% |
|
Jun 2025 (Q2)
|
$-0.75 | $-0.85 | +0.0983 | +11.59% |
|
Mar 2025 (Q1)
|
$-0.68 | $-0.78 | +0.0952 | +12.28% |
|
Dec 2024 (Q4)
|
$-0.57 | $-0.64 | +0.0675 | +10.59% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $12.41M |
| Operating Expenses | $110.11M |
| Research and Development | $81.73M |
| Other Operating Expenses | $28.38M |
| Operating Income/Loss | -$110.11M |
| Income/Loss From Continuing Operations After Tax | -$97.69M |
| Income/Loss From Continuing Operations Before Tax | -$97.70M |
| Net Income/Loss | -$97.70M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$97.69M |
| Net Income/Loss Available To Common Stockholders, Basic | -$97.70M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.27 |
| Diluted Earnings Per Share | -$2.27 |
| Basic Average Shares | 78,099,829 |
| Diluted Average Shares | 78,099,829 |
| Assets | $535.32M |
| Current Assets | $520.66M |
| Cash | $513.00M |
| Other Current Assets | $7.66M |
| Noncurrent Assets | $14.66M |
| Fixed Assets | $3.12M |
| Other Non-current Assets | $11.55M |
| Liabilities | $23.71M |
| Current Liabilities | $14.32M |
| Accounts Payable | $3.24M |
| Wages | $5.04M |
| Other Current Liabilities | $6.05M |
| Noncurrent Liabilities | $9.39M |
| Equity | $511.62M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $511.62M |
| Liabilities And Equity | $535.32M |
| Net Cash Flow From Operating Activities | -$77.22M |
| Net Cash Flow From Operating Activities, Continuing | -$77.22M |
| Net Cash Flow From Investing Activities | $18.78M |
| Net Cash Flow From Investing Activities, Continuing | $18.78M |
| Net Cash Flow From Financing Activities | $270.48M |
| Net Cash Flow From Financing Activities, Continuing | $270.48M |
| Net Cash Flow | $212.05M |
| Net Cash Flow, Continuing | $212.05M |
| Comprehensive Income/Loss | -$97.42M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$97.96M |
| Other Comprehensive Income/Loss | $271.00K |
| Other Comprehensive Income/Loss Attributable To Parent | -$255.00K |